Page last updated: 2024-11-12

chlortetracycline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54675777
CHEMBL ID404520
CHEMBL ID1622557
CHEBI ID27644
SCHEMBL ID62861
SCHEMBL ID3110
SCHEMBL ID4099094
SCHEMBL ID19981439
MeSH IDM0004211

Synonyms (92)

Synonym
KBIO1_000253
DIVK1C_000253
(4s,4as,5as,6s,12as)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
acronize
epa pesticide chemical code 006301
clortetraciclina [inn-spanish]
einecs 200-341-7
caswell no. 219b
aureomycin a-377
chlortetracycline [inn:ban]
chlortetracyclinum [inn-latin]
SPECTRUM_000727
SPECTRUM_001315
SPECTRUM4_001791
IDI1_000253
SPECTRUM5_000461
NCGC00178862-01
chlortetracycline (inn)
D07689
PRESTWICK2_000145
chlorotetracycline
7-chlorotetracycline
chlortetracycline
57-62-5
C06571
aureomycin (tn)
KBIO3_001235
KBIOGR_001461
KBIOSS_001207
KBIOGR_002364
KBIO2_001795
KBIO2_006931
KBIO2_004363
KBIO2_006343
KBIO2_003775
KBIOSS_001795
KBIO2_001207
NINDS_000253
SPECTRUM4_001001
PRESTWICK0_000145
PRESTWICK1_000145
SPECTRUM2_000802
SPBIO_000663
SPBIO_002189
SPECTRUM3_000348
BSPBIO_002015
SPECTRUM5_001870
LMPK07000004
HMS500M15
CHEMBL404520
chebi:27644 ,
e702
CHEMBL1622557
clortetraciclina
chlortetracyclinum
wck1kiq23q ,
chlormax
unii-wck1kiq23q
chlortetracycline [inn]
chlortetracycline [green book]
chlortetracycline [mart.]
lymecycline impurity g [ep impurity]
chlortetracycline [vandf]
chlortetracycline [ep impurity]
chlortetracycline [mi]
chlortetracycline [who-dd]
SCHEMBL62861
SCHEMBL3110
SCHEMBL4099094
Q-200843
aueromycin
SCHEMBL19981439
AB00643434_03
mfcd00864876
DTXSID9022811 ,
DB09093
AKOS027381845
SBI-0051312.P003
rkl10090
(4s,5as,6s,12as)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
NCGC00178862-04
HY-B1327A
Q417948
CYDMQBQPVICBEU-XRNKAMNCSA-N
CCG-269531
H10649
CS-0013541
EN300-19651945
pig muscle (ctc free)
pig liver-chlortetracycline
pig kidney (ctc free)
722 - tetracyclines in pork

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Two common freshwater phytoplankton species Microcystis aeruginosa and Scenedesmus obliquus were employed as test organisms to investigate the toxic effects of chlortetracycline widely used in human medicine and veterinary as antibiotic."( Phytoplankton toxicity of the antibiotic chlortetracycline and its UV light degradation products.
Chen, JQ; Guo, RX, 2012
)
0.38
" Electron beam treatment could be an effective and safe method for the removal of antibiotic compounds."( Degradation and toxicity assessment of sulfamethoxazole and chlortetracycline using electron beam, ozone and UV.
Kim, HY; Kim, SD; Kim, TH; Lee, M; Lim, SJ; Yu, S, 2012
)
0.38
" CTC-metal complexes were more toxic than the CTC itself for Bt whereas for Ea, CTC and its metal complexes showed similar toxicity."( Toxicity of chlortetracycline and its metal complexes to model microorganisms in wastewater sludge.
Brar, SK; Das, RK; Drogui, P; Pulicharla, R; Sarma, SJ; Surampalli, RY; Valero, JR; Verma, M, 2015
)
0.42
"Tetracyclines belong to antimicrobial classes with the highest consumption in veterinary medicine and agriculture, which leads to the contamination of the environment and food products, as well as to antibiotic resistance and adverse drug reactions."( Chlortetracycline and melanin biopolymer - The risk of accumulation and implications for phototoxicity: An in vitro study on normal human melanocytes.
Beberok, A; Respondek, M; Rok, J; Rzepka, Z; Wrześniok, D, 2019
)
0.51
"The increase of concentrations of tetracycline antibiotics in agricultural soils worldwide is of special concern, due to its potential toxic effects on soil bacterial communities."( Use of waste materials to prevent tetracycline antibiotics toxicity on the growth of soil bacterial communities.
Álvarez-Rodríguez, E; Arias-Estévez, M; Díaz-Raviña, M; Fernández-Calviño, D; Fernández-Sanjurjo, MJ; Núñez-Delgado, A; Santás-Miguel, V, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
"A physiologically based pharmacokinetic model was developed to describe the absorption and disposition of chlortetracyline (CTC) in the healthy and diseased (fowl cholera) turkey."( The pharmacokinetics of chlortetracycline orally administered to turkeys: influence of citric acid and Pasteurella multocida infection.
Dyer, DC; Glatz, CE; Pollet, RA, 1985
)
0.27
" The oral time-course drug data were fitted adequately by a 2-compartment pharmacokinetic model with absorption."( Pharmacokinetics of chlortetracycline potentiation with citric acid in the chicken.
Barnes, HJ; Dyer, DC; Glatz, CE; Pollet, RA, 1983
)
0.27
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" However, pharmacokinetic parameters for CTC in ruminating cattle are unavailable in peer-reviewed literature."( Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting.
Apley, MD; Coetzee, JF; Gehring, R; Havel, JA; Hollis, LC; Olson, KC; Reinbold, JB, 2010
)
0.36
"The objectives of this study were to determine plasma concentrations and pharmacokinetic parameters of feed-grade chlortetracycline (CTC) in sheep after oral administration of 80 or 500 mg/head daily, divided into two equal doses given at 12-h intervals for 8 days."( Pharmacokinetics of oral chlortetracycline in nonpregnant adult ewes.
Coetzee, JF; Fajt, VR; Plummer, P; Washburn, K; Washburn, S; Wulf, LW, 2014
)
0.4

Compound-Compound Interactions

The objective of this research was to comprehensively quantify the effects of feeding laidlomycin propionate (LP), alone and/or in combination with chlortetracycline, compared with monensin sodium.

ExcerptReferenceRelevance
"The objective of this research was to use data from multiple studies to comprehensively quantify the effects of feeding 1) laidlomycin propionate (LP), alone and/or in combination with chlortetracycline, compared with 2) monensin sodium (MS), alone and/or in combination with tylosin, at commercially approved dosages, on ADG, DMI, feed efficiency (FE), mortality, and carcass characteristics (HCW and liver abscesses)."( Meta-analysis of the effects of laidlomycin propionate, fed alone or in combination with chlortetracycline, compared with monensin sodium, fed alone or in combination with tylosin, on growth performance, health, and carcass outcomes in finishing steers in
Branine, M; Cernicchiaro, N; Corbin, M; Prouty, F; Quinn, M; Renter, DG, 2016
)
0.43
" In a second challenge study, the dose rate of tiamulin combined with chlortetracycline was tested."( Efficacy of tiamulin alone or in combination with chlortetracycline against experimental Mycoplasma gallisepticum infection in chickens.
Degussem, K; Depondt, W; Garmyn, A; Haesebrouck, F; Martel, A; Vereecken, M, 2017
)
0.46

Bioavailability

The aim of this work is to improve the solubility and bioavailability of chlortetracycline and the function of the immune response. The study involved 18 piglets divided into three groups (A, B and C)

ExcerptReferenceRelevance
"In a study involving 18 piglets divided into three groups (A, B and C), the effects of dietary calcium and citric acid, and feeding technique on chlortetracycline bioavailability were examined."( Influence of dietary citric acid and calcium on the bioavailability of orally administered chlortetracycline in piglets.
Broz, J; Riond, JL; Sutter, HM; Walker, W; Wanner, M, 1991
)
0.28
" The bioavailability for both groups was similar; 19."( Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs.
Bane, DP; Bevill, RF; Hall, WF; Kilroy, CR; Koritz, GD, 1990
)
0.28
"The influence of different modes of feeding on the bioavailability of orally administered chlortetracycline was studied in weaned pigs."( [The effect of feed preparation on the pharmacokinetics of peroral administration of chlortetracycline in weaned piglets].
Sutter, HM; Wanner, M, 1990
)
0.28
" The resulting absorption rate constant (Ka) for the birds orally given CTC with citric acid was nearly equal to that for the birds given CTC alone."( Pharmacokinetics of chlortetracycline potentiation with citric acid in the chicken.
Barnes, HJ; Dyer, DC; Glatz, CE; Pollet, RA, 1983
)
0.27
"The bioavailability of oxytetracycline (OTC) and chlortetracycline (CTC) was studied in non-fasting calves."( The availability of tetracyclines in calves.
Jacobsson, SO; Luthman, J,
)
0.13
" The bioavailability was in general low for all the three tetracyclines."( Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs.
Gyrd-Hansen, N; Nielsen, P, 1996
)
0.29
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" These compounds are poorly absorbed during digestion so that the bioactive compound or metabolites are excreted."( Effect of antimicrobial compounds tylosin and chlortetracycline during batch anaerobic swine manure digestion.
Clay, SA; Porath, LR; Spellman, GM; Stone, JJ; Wong, KL; Zhu, Z, 2009
)
0.35
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
" A one-compartment open model with first order absorption and elimination, where absorption rate constant was equal to elimination rate constant, was fitted using nonlinear mixed effects modeling (NLMEM)."( Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting.
Apley, MD; Coetzee, JF; Gehring, R; Havel, JA; Hollis, LC; Olson, KC; Reinbold, JB, 2010
)
0.36
" Oral bioavailability was 17."( Plasma disposition and tissue depletion of chlortetracycline in the food producing animals, chickens for fattening.
Anadón, A; Ares, I; Castellano, V; Gamboa, F; Martínez, M; Martínez, MA; Martínez-Larrañaga, MR; Ramos, E; Suarez, FH, 2012
)
0.38
" Thus, exposure to T-2-contaminated feed can influence the oral bioavailability of chlortetracycline."( Chronic exposure to the mycotoxin T-2 promotes oral absorption of chlortetracycline in pigs.
Croubels, S; De Backer, P; De Baere, S; Devreese, M; Goossens, J; Haesebrouck, F; Osselaere, A; Pasmans, F; Verbrugghe, E, 2013
)
0.39
"The poor oral bioavailability of tetracyclines resulted in rather high concentrations in cecal and colonic content and feces at steady-state conditions."( Residues of chlortetracycline, doxycycline and sulfadiazine-trimethoprim in intestinal content and feces of pigs due to cross-contamination of feed.
Butaye, P; Croubels, S; Daeseleire, E; Devreese, M; Dewulf, J; Haesebrouck, F; Heyndrickx, M; Imberechts, H; Peeters, LE; Rasschaert, G; Smet, A, 2016
)
0.43
"The relation between the oral bioavailability and intestinal concentrations of the tested antimicrobials, may be of help in assessing the risks of cross-contaminated feed."( Residues of chlortetracycline, doxycycline and sulfadiazine-trimethoprim in intestinal content and feces of pigs due to cross-contamination of feed.
Butaye, P; Croubels, S; Daeseleire, E; Devreese, M; Dewulf, J; Haesebrouck, F; Heyndrickx, M; Imberechts, H; Peeters, LE; Rasschaert, G; Smet, A, 2016
)
0.43
"The aim of this work is to improve the solubility and bioavailability of chlortetracycline and the function of the immune response."( Synthesis and evaluation of bisulfate/mesylate-conjugated chlortetracycline with high solubility and bioavailability.
Chen, P; Liu, D; Wang, J; Yang, X, 2020
)
0.56
"We speculated that gut microbiota is no longer sensitive to a low concentration of CTC due to the long-term use and low bioavailability of CTC in weaned piglets."( Effects of chlortetracycline on growth performance and intestinal functions in weaned piglets.
Han, H; Tang, C; Yin, J; Zhang, H; Zhang, J; Zhang, S; Zhong, R, 2022
)
0.72
" The focus of the present pilot study was to assess whether vascular perfusion of the well tolerated and characterized chlortetracycline (widely used as an orally bioavailable antibiotic) can fluorescently label retinal HAP using human cadavers."( Fluorescence Lifetime Imaging of Human Sub-RPE Calcification In Vitro Following Chlortetracycline Infusion.
Fuller, K; Hegde, KR; Lengyel, I; Patel, N; Puche, AC; Ray, K; Szmacinski, H; Thompson, RB, 2023
)
0.91
"Copper (Cu) and tetracyclines (TCs) often coexist in agricultural soils because of the use of manures on farmland; however, the influence of Cu on the bioavailability of TCs is still unclear, especially for cases with aging Cu."( Influence of copper and aging on freely dissolved tetracycline concentration in soil.
Guo, R; He, J; Li, L; Li, X; Ma, W; Wang, Y; Zhu, D, 2023
)
0.91

Dosage Studied

18 piglets were fed either a dry, humid or soup diet. Each animal was dosed with 40 mg chlortetracycline/kg bodyweight. 110 of the reactors (from 7 herds) were tested after being treated orally for 45 days.

ExcerptRelevanceReference
" A new general equation relating the response of the test organism to concentrations of active materials was used to account for factors in addition to the antibiotic upon the dose-response line."( Automated system for analytical microbiology V: calibration lines for antibiotics.
Kavanagh, F, 1975
)
0.25
" Up to this time, amoxicillin has not been commercially available as an injectable dosage form."( Pneumococcal meningitis-therapeutic studies in mice.
Hirth, RS; Price, KE; Tsai, YH; Williams, EB, 1975
)
0.25
" The developed method was successfully applied to the determination of chlortetracycline in various dosage forms."( Paper chromatographic determination of chlortetracycline.
Attia, IA; Safwat, S; Youssef, MK, 1978
)
0.26
"5%) were reactors; 110 of the reactors (from 7 herds) were tested after being treated orally for 45 days with chlortetracycline or oxytetracycline at a calculated daily dosage of 11 mg/kg of body weight, and all were seronegative."( Anaplasmosis: a regional serologic survey and oral antibiotic therapy in infected herds.
Stauber, EH; Sweet, VH, 1978
)
0.26
" Five of the pigs were fasted 18 h prior to dosing and five of the pigs were fed ad libitum prior to dosing."( Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs.
Bane, DP; Bevill, RF; Hall, WF; Kilroy, CR; Koritz, GD, 1990
)
0.28
" CTC was applied at a concentration of 6000 ppm and 2500 ppm to each diet and the oral dosage of CTC was 40 mg chlortetracycline/kg bodyweight."( [The effect of feed preparation on the pharmacokinetics of peroral administration of chlortetracycline in weaned piglets].
Sutter, HM; Wanner, M, 1990
)
0.28
"18 piglets were fed either a dry, humid or soup diet and each animal was dosed with 40 mg chlortetracycline/kg bodyweight."( [Feed preparation and pharmacokinetics of chlortetracycline in piglets].
Sutter, HM; Wanner, M, 1990
)
0.28
"After dosing laying hens orally with tetracycline (TC) through either drinking water (0."( Excretion of tetracycline and chlortetracycline in eggs after oral medication of laying hens.
Boisseau, J; Moretain, JP; Roudaut, B,
)
0.13
" The dose-response curve of the fluorescence change and that of the superoxide release of th cells were very similar."( Release of the membrane-calcium and its relation to the superoxide formation by polymorphonuclear leukocytes.
Matsumoto, T; Minakami, S; Nabi, ZF; Takeshige, K, 1982
)
0.26
"1 g/liter) were present in the drinking water and dosage solution than when citric acid was omitted."( Oral absorption of chlortetracycline in turkeys: influence of citric acid and Pasteurella multocida infection.
Dyer, DC; Glatz, CE; Pollet, RA, 1984
)
0.27
" The two groups receiving a therapeutic dosage of oxytetracycline had the most quickly declining body temperatures and the highest average body weights post-challenge."( Subtherapeutic tetracycline effects on recovery patterns of calves after Salmonella typhimurium challenge.
Avens, JS; Johnson, DE; Remillard, RL, 1981
)
0.26
" Among the critical factors that can be controlled by the analyst are careful weighing of the reference standard and careful dosing of cylinders."( Some factors affecting assay variability in the determination of chlortetracycline in premix feeds.
Ragheb, HS, 1980
)
0.26
" It is concluded that: firstly, recommended CTC withdrawal periods are sufficient to avoid violative carcass residues; secondly, violative residues do not arise from sub-therapeutic dosing but can arise from supra-therapeutic dosing which could occur with inadequately mixed feed; and thirdly, the difference in kidney cortex and medullary CTC concentrations is significant from a regulatory perspective."( Origin of chlortetracycline in pig tissue.
Crooks, SR; Elliott, CT; Kennedy, DG; McCaughey, WJ; McEvoy, JD, 1994
)
0.29
" Our results suggest that, if the label withdrawal period of 10 days is observed, an increase in the dosage of up to three times the recommended rate is unlikely to increase significantly the risk that residues would occur in the tissues of treated hogs at concentrations which exceed MRLs."( Residue depletion in tissues and fluids from swine fed sulfamethazine, chlortetracycline and penicillin G in combination.
Fesser, AC; Korsrud, GO; MacNeil, JD; Papich, MG; Salisbury, CD, 1996
)
0.29
" Only by increasing the dosage of antibiotics to a therapeutic level does antibiotic metaphylaxis surpass homeopathic metaphylaxis."( Homeopathy versus antibiotics in metaphylaxis of infectious diseases: a clinical study in pig fattening and its significance to consumers.
Albrecht, H; Schütte, A, 1999
)
0.3
" The routine antibiotic dosage of metaphylaxis is too low to be effective."( Homeopathy versus antibiotics in metaphylaxis of infectious diseases: a clinical study in pig fattening and its significance to consumers.
Albrecht, H; Schütte, A, 1999
)
0.3
" Pigs were dosed orally with CTC for three days, and given injections of Salmonella LPS 24 h before removal of the liver."( Chlortetracycline modulates acute phase response of ex vivo perfused pig livers, and inhibits TNF-alpha secretion by isolated Kupffer cells.
Ahrens, FA; Akunda, JK; Johnson, E; Kramer, TT, 2001
)
0.31
" For most practical purposes, however, both preparations may be regarded as substantially pure, and it is considered that to alter the present practice of quoting aureomycin dosage in metric units of weight would be inadvisable."( The international standard for aureomycin.
HUMPHREY, JH; LIGHTBOWN, JW; MUSSETT, MV; PERRY, WL, 1953
)
0.23
" Tetracycline, oxytetracycline, chlortetracycline and minocycline all effectively induced the resulting Escherichia coli MC4100/pTGM biosensor and similar dose-response characteristics were recorded by flow cytometry for all four compounds."( Construction of an extended range whole-cell tetracycline biosensor by use of the tet(M) resistance gene.
Bahl, MI; Hansen, LH; Sørensen, SJ, 2005
)
0.33
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" did not appear to be influenced by dosing treatment including the control."( Effect of antimicrobial dosage regimen on Salmonella and Escherichia coli isolates from feeder swine.
Dargatz, DA; Fedorka-Cray, PJ; Straw, BE; Wagner, BA, 2008
)
0.35
" Groups of pigs were dosed orally with isogenic pTENT2-positive and pTENT2-negative ETEC strains, and the clinical and pathological changes were compared between the groups."( Effect of plasmid pTENT2 on severity of porcine post-weaning diarrhoea induced by an O149 enterotoxigenic Escherichia coli.
Boerlin, P; Friendship, RM; Goswami, PS; Gyles, CL; Kozak, GK; Poppe, C, 2008
)
0.35
" The control diet, containing only SAL at 60 mg/kg, was fed to all birds throughout the 35-d trial, including the period during the gaps between dosing (i."( Compatibility of a combination of tiamulin and chlortetracycline with salinomycin in feed during a pulsed medication program coadministration in broilers.
Afrin, S; Burch, DG; Das, PM; Hassan, MM; Islam, KM; Kemppainen, BW; Klein, U; Valks, M, 2008
)
0.35
" Currently, gestating sows and gilts receive chlortetracycline in feed at a dosage of 22 mg/kg/d for 2 weeks beginning 3 weeks prior to farrowing."( Dysgalactia associated with Mycoplasma suis infection in a sow herd.
Hawkins, PA; Strait, EL; Wilson, WD, 2012
)
0.38
" Blood samples were collected just prior to dosing at 0, 12, 24, 72, 96, and 192 h, as well as 4, 8, 12, 24, and 36 h after the last dose, and noncompartmental pharmacokinetic analysis was performed to estimate elimination half-life and area under the plasma concentration-time curve (AUC)."( Pharmacokinetics of oral chlortetracycline in nonpregnant adult ewes.
Coetzee, JF; Fajt, VR; Plummer, P; Washburn, K; Washburn, S; Wulf, LW, 2014
)
0.4
" These results show that the effect of antibiotics on the swine gut microbiota is variable based on dosage and duration and that the swine gut microbiota exhibits considerable resilience to long-term changes due to antibiotic perturbations."( Temporal changes and the effect of subtherapeutic concentrations of antibiotics in the gut microbiota of swine.
Chénier, MR; Holman, DB, 2014
)
0.4
" The effects various factors on the adsorption of CTC by La-Z were investigated, including the lanthanum modification concentration on zeolites, the dosage of La-Z, solution pH and reaction time."( Adsorption of chlortetracycline from aquaculture wastewater using modified zeolites.
Liao, J; Tian, S; Xue, B; Yu, R; Yu, X; Zhu, W, 2020
)
0.56
" The results show that the dosage of 5-10 mg/L TCMP daily effectively inhibited nitrification."( The effect of nitrification inhibitors on the aerobic biodegradation of tetracycline antibiotics in swine wastewater.
Bai, L; Cao, G; Chen, X; Meng, S; Xue, W; Yang, L; Yuan, C, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)IC50 (µMol)100.00000.00001.068010.0000AID723886
P2Y purinoceptor 12Homo sapiens (human)Ki10.00000.00202.82209.8300AID375433
Protein-arginine deiminase type-4Homo sapiens (human)IC50 (µMol)100.00002.50004.20005.9000AID320706
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
sensory perception of smellcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of protein kinase A signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
monoatomic ion transportP2Y purinoceptor 12Homo sapiens (human)
substrate-dependent cell migration, cell extensionP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
hemostasisP2Y purinoceptor 12Homo sapiens (human)
calcium-mediated signalingP2Y purinoceptor 12Homo sapiens (human)
cerebral cortex radial glia-guided migrationP2Y purinoceptor 12Homo sapiens (human)
cell projection organizationP2Y purinoceptor 12Homo sapiens (human)
lamellipodium assemblyP2Y purinoceptor 12Homo sapiens (human)
platelet activationP2Y purinoceptor 12Homo sapiens (human)
positive regulation of integrin activation by cell surface receptor linked signal transductionP2Y purinoceptor 12Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
positive regulation of monoatomic ion transportP2Y purinoceptor 12Homo sapiens (human)
response to axon injuryP2Y purinoceptor 12Homo sapiens (human)
regulation of chemotaxisP2Y purinoceptor 12Homo sapiens (human)
positive regulation of chemotaxisP2Y purinoceptor 12Homo sapiens (human)
establishment of localization in cellP2Y purinoceptor 12Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionP2Y purinoceptor 12Homo sapiens (human)
platelet aggregationP2Y purinoceptor 12Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 12Homo sapiens (human)
visual system developmentP2Y purinoceptor 12Homo sapiens (human)
positive regulation of ruffle assemblyP2Y purinoceptor 12Homo sapiens (human)
regulation of microglial cell migrationP2Y purinoceptor 12Homo sapiens (human)
positive regulation of microglial cell migrationP2Y purinoceptor 12Homo sapiens (human)
chromatin organizationProtein-arginine deiminase type-4Homo sapiens (human)
nucleosome assemblyProtein-arginine deiminase type-4Homo sapiens (human)
chromatin remodelingProtein-arginine deiminase type-4Homo sapiens (human)
stem cell population maintenanceProtein-arginine deiminase type-4Homo sapiens (human)
protein modification processProtein-arginine deiminase type-4Homo sapiens (human)
post-translational protein modificationProtein-arginine deiminase type-4Homo sapiens (human)
innate immune responseProtein-arginine deiminase type-4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled adenosine receptor activityP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 12Homo sapiens (human)
guanyl-nucleotide exchange factor activityP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 12Homo sapiens (human)
protein-arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
calcium ion bindingProtein-arginine deiminase type-4Homo sapiens (human)
protein bindingProtein-arginine deiminase type-4Homo sapiens (human)
identical protein bindingProtein-arginine deiminase type-4Homo sapiens (human)
histone arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R2 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R8 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R17 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R26 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
ruffle membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membraneP2Y purinoceptor 12Homo sapiens (human)
cell surfaceP2Y purinoceptor 12Homo sapiens (human)
membraneP2Y purinoceptor 12Homo sapiens (human)
cell projection membraneP2Y purinoceptor 12Homo sapiens (human)
cell body membraneP2Y purinoceptor 12Homo sapiens (human)
nucleusProtein-arginine deiminase type-4Homo sapiens (human)
nucleoplasmProtein-arginine deiminase type-4Homo sapiens (human)
cytosolProtein-arginine deiminase type-4Homo sapiens (human)
protein-containing complexProtein-arginine deiminase type-4Homo sapiens (human)
nucleusProtein-arginine deiminase type-4Homo sapiens (human)
cytoplasmProtein-arginine deiminase type-4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (63)

Assay IDTitleYearJournalArticle
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540235Phospholipidosis-negative literature compound
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID575170Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID608203Binding affinity to recombinant TetR(D) expressed in Escherichia coli RB791 by fuorescence assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Recognition of drug degradation products by target proteins: isotetracycline binding to Tet repressor.
AID396000Antimicrobial activity against Mycoplasma putrefaciens French isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1566490Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation at 1 mM measured after 15 mins by cat-ELCCA relative to control2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID320708Inhibition of PAD4 measured by intercept plot of Lineweaver-Burke analyses2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID396002Antimicrobial activity against Mycoplasma putrefaciens KS1 after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID1566489Inhibition of biotinylated pre-let-7d microRNA (unknown origin) maturation preincubated for 15 mins followed by Pre-let-7d addition and measured after 5 hrs by cat-ELCCA2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID723886Inhibition of PAD4 (unknown origin)2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Novel inhibitors of protein arginine deiminase with potential activity in multiple sclerosis animal model.
AID320706Inhibition of PAD4 by ABPP-based assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
AID575168Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in marR mutant containing Escherichia coli K-12 3-AG102 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric a2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID575169Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID396001Antimicrobial activity against Mycoplasma putrefaciens Jordanian isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID320707Inhibition of PAD4 measured by slope plot of Lineweaver-Burke analyses2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID608202Binding affinity to recombinant TetR(D) expressed in Escherichia coli RB791 by SPR analysis2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Recognition of drug degradation products by target proteins: isotetracycline binding to Tet repressor.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID375433Displacement of [3H]PSB0413 from human platelet P2Y12 receptor2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID575167Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in marR mutant containing Escherichia coli K-12 3-AG102 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric 2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID375434Displacement of [3H]PSB0413 from human platelet P2Y12 receptor at 10 uM2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID575165Inhibition of acrAB AcrAB-TolC in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as [3H]TMG accumulation at 200 uM by scintillation counter method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1566488Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation preincubated for 15 mins followed by pre-miRNA-21 addition and measured after 5 hrs by cat-ELCCA2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,967)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904213 (84.82)18.7374
1990's150 (3.02)18.2507
2000's190 (3.83)29.6817
2010's274 (5.52)24.3611
2020's140 (2.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials65 (1.16%)5.53%
Reviews58 (1.04%)6.00%
Case Studies39 (0.70%)4.05%
Observational0 (0.00%)0.25%
Other5,421 (97.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]